Valuation: Galderma Group AG

Capitalization 48.81B 41.58B 38.84B 36.54B 67.28B 4,421B 73.5B 453B 176B 2,084B 183B 179B 7,603B P/E ratio 2025 *
98.5x
P/E ratio 2026 * 57.3x
Enterprise value 50.82B 43.3B 40.44B 38.05B 70.06B 4,603B 76.54B 472B 183B 2,170B 191B 187B 7,917B EV / Sales 2025 *
9.59x
EV / Sales 2026 * 8.04x
Free-Float
35.38%
Yield 2025 *
0.15%
Yield 2026 * 0.28%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.25%
1 week+0.49%
Current month+2.25%
1 month+6.93%
3 months+12.21%
6 months+46.07%
Current year+62.56%
More quotes
1 week 162.2
Extreme 162.2
170.1
1 month 143
Extreme 143
170.1
Current year 72.7
Extreme 72.7
170.1
1 year 72.7
Extreme 72.7
170.1
3 years 60
Extreme 60
170.1
5 years 60
Extreme 60
170.1
10 years 60
Extreme 60
170.1
More quotes
Change 5d. change 1-year change 3-years change Capi.($)
+0.25%+0.49%+81.35% - 48.81B
-0.51%-0.72%+7.42%+5.82% 232B
+0.80%+1.70%-6.14%+15.65% 18.37B
+5.27%+3.94%-13.96%-62.85% 6.25B
0.00%-2.01%+9.04%-7.73% 5.14B
-2.09%-6.19%-41.94%+39.88% 4.55B
+0.90%-2.43%+125.67% - 4.32B
-0.13%-1.97%-29.95%-41.70% 3.78B
-3.59%-6.67%-56.89%-59.34% 2.82B
+1.68%+1.75%-38.78%-12.85% 2.7B
Average +0.26%-1.12%+3.58%-15.39% 32.83B
Weighted average by Cap. -0.21%-0.46%+16.78%+3.72%
See all sector performances

Financials

2025 *2026 *
Net sales 5.2B 4.43B 4.14B 3.89B 7.17B 471B 7.83B 48.28B 18.73B 222B 19.5B 19.09B 810B 6.17B 5.26B 4.91B 4.62B 8.5B 559B 9.29B 57.31B 22.23B 263B 23.15B 22.66B 961B
Net income 552M 470M 439M 413M 761M 50B 831M 5.13B 1.99B 23.57B 2.07B 2.03B 85.99B 891M 759M 709M 667M 1.23B 80.73B 1.34B 8.28B 3.21B 38.05B 3.34B 3.27B 139B
Net Debt 2.02B 1.72B 1.6B 1.51B 2.78B 183B 3.04B 18.73B 7.27B 86.11B 7.57B 7.41B 314B 1.25B 1.06B 993M 934M 1.72B 113B 1.88B 11.59B 4.5B 53.28B 4.68B 4.58B 194B
More financial data * Estimated data
Logo Galderma Group AG
Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.
Employees
-
More about the company
Date Price Change Volume
25-12-12 163.60 CHF +0.25% 343,655
25-12-11 163.20 CHF -2.74% 359,711
25-12-10 167.80 CHF +1.39% 464,983
25-12-09 165.50 CHF +0.61% 343,034
25-12-08 164.50 CHF +1.04% 417,190

Delayed Quote Swiss Exchange, December 12, 2025 at 11:31 am EST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
205.59USD
Average target price
198.15USD
Spread / Average Target
-3.62%
Consensus

Quarterly revenue - Rate of surprise